 Alisa B. Lee Sherick
| Title | Asst Professor |
|---|
| Institution | University of Colorado Denver - Anschutz Medical Campus |
|---|
| Department | SOM-PEDS |
|---|
|
|
|
 Overview Dr. Lee-Sherick is a Pediatric Bone Marrow Transplant specialist at Children's Hospital Colorado. Dr. Lee Sherick's primary research focus is to harness the immune system to more effectively cure acute leukemia. The Lee Sherick lab explores the role that tolerogenic macrophages and dendritic cells play in immune evasion of leukemia and how this can be reversed. One such approach is by inhibiting efferocytosis by blocking phosphatidyl serine receptors (such as MerTK) on macrophages and dendritic cells, which results in an anti-tumor microenvironment and decreases immune evasion. The hope is that the knowledge gained from this research can be used to develop novel immunotherapeutic approaches to treat acute leukemias.
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
-
DeRyckere D, Lee-Sherick AB, Huey MG, Hill AA, Tyner JW, Jacobsen KM, Page LS, Kirkpatrick GG, Eryildiz F, Montgomery SA, Zhang W, Wang X, Frye SV, Earp HS, Graham DK. UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clin Cancer Res. 2017 Mar 15; 23(6):1481-1492. PMID: 27649555.
-
Lee-Sherick AB, Eisenman KM, Sather S, McGranahan A, Armistead PM, McGary CS, Hunsucker SA, Schlegel J, Martinson H, Cannon C, Keating AK, Earp HS, Liang X, DeRyckere D, Graham DK. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene. 2016 Dec 01; 35(48):6270. PMID: 27593932.
-
Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, Jordan CT, Kireev D, Wang X, Frye SV, Earp HS, Shah NP, Graham DK. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar; 1(3):e85630. PMID: 27158668.
-
Lee-Sherick AB, Zhang W, Menachof KK, Hill AA, Rinella S, Kirkpatrick G, Page LS, Stashko MA, Jordan CT, Wei Q, Liu J, Zhang D, DeRyckere D, Wang X, Frye S, Earp HS, Graham DK. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget. 2015 Mar 30; 6(9):6722-36. PMID: 25762638; PMCID: PMC4466645.
-
Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savoia A, Rajpurkar M, Jones K, Gowan K, Balduini C, Pecci A, Gnan C, De Rocco D, Doubek M, Li L, Lu L, Leung R, Landolt-Marticorena C, Hunger S, Heller P, Gutierrez-Hartmann A, Xiayuan L, Pluthero FG, Rowley JW, Weyrich AS, Kahr WHA, Porter CC, Di Paola J. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015 May; 47(5):535-538. PMID: 25807284; PMCID: PMC4631613.
-
Christoph S, Lee-Sherick AB, Sather S, DeRyckere D, Graham DK. Pre-clinical evaluation of tyrosine kinase inhibitors for treatment of acute leukemia. J Vis Exp. 2013 Sep 18; (79):e50720. PMID: 24084362; PMCID: PMC3923888.
-
Linger RM, Lee-Sherick AB, DeRyckere D, Cohen RA, Jacobsen KM, McGranahan A, Brandão LN, Winges A, Sawczyn KK, Liang X, Keating AK, Tan AC, Earp HS, Graham DK. Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. Blood. 2013 Aug 29; 122(9):1599-609. PMID: 23861246; PMCID: PMC3757372.
-
Lee-Sherick AB, Eisenman KM, Sather S, McGranahan A, Armistead PM, McGary CS, Hunsucker SA, Schlegel J, Martinson H, Cannon C, Keating AK, Earp HS, Liang X, DeRyckere D, Graham DK. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene. 2013 Nov 14; 32(46):5359-68. PMID: 23474756; PMCID: PMC3898106.
-
Lee-Sherick AB, Linger RM, Gore L, Keating AK, Graham DK. Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol. 2010 Nov; 151(4):295-311. PMID: 20813012; PMCID: PMC3354740.
-
Lee AB, Harker-Murray P, Ferrieri P, Schleiss MR, Tolar J. Bacterial meningitis from Rothia mucilaginosa in patients with malignancy or undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2008 Mar; 50(3):673-6. PMID: 17588235.
-
Wang H, Grzywacz B, Sukovich D, McCullar V, Cao Q, Lee AB, Blazar BR, Cornfield DN, Miller JS, Verneris MR. The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations. Blood. 2007 Sep 01; 110(5):1530-9. PMID: 17495133; PMCID: PMC1975839.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
| Year | Publications |
|---|
| 2007 | 1 | | 2008 | 1 | | 2010 | 1 | | 2013 | 3 | | 2015 | 2 | | 2016 | 3 |
To return to the timeline, click here.
|
Lee Sherick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|